Panacea currently has active programs in cancer, stroke/ischemia, Alzheimer's Disease, and Parkinson's Disease.

Panacea's product development approach integrates the best possible science with the best possible management. We establish and nurture collaborations with leaders in the fields of science and medicine in which we work, and then manage them proactively to ensure rapid, efficient progression from target discovery through product development to the market. The Company's management approach involves bringing creativity and fresh thinking to R & D while at the same time maintaining careful, consistent attention to the details of financial and project management.

Our model is to discover new targets through collaborations and internal R&D or to in-license promising early-stage targets, then add value to the targets by accelerating the screening and selection of candidate therapeutics and their subsequent progression through the biopharmaceutical product life cycle. Products are advanced as far in the pipeline as possible with internal resources and expertise before partnering with larger biopharmaceutical companies for development and/or commercialization. The Company also is committed to building an intellectual property portfolio that emphasizes broad, enabling platform technologies and discoveries.